Skip to main content
Swing Capital

Jubilant Pharmova Ltd

NSE: JUBLPHARMA BSE: 530019

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

₹1,001
52W: ₹784 — ₹1250
PE 0 · Book ₹141 · +610% vs book
Market Cap₹15,953 Cr
Stock P/E—Price to Earnings
ROCE2.91%Return on Capital
ROE1.04%Return on Equity
Div. Yield0.51%Face Value ₹1

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 275%

Weaknesses

  • −Stock is trading at 7.12 times its book value
  • −The company has delivered a poor sales growth of -25.0% over past five years.
  • −Company has a low return on equity of 1.49% over last 3 years.
  • −Earnings include an other income of Rs.58.2 Cr.
  • −Company's cost of borrowing seems high
  • −Promoter holding has decreased over last 3 years: -3.01%

Shareholding Pattern

Promoters47.67%
FIIs15.9%
DIIs11.63%
Public24.25%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters50.67%50.67%50.67%50.67%47.67%▼3.047.67%47.67%47.67%
FIIs19.5%17.94%▼1.616.96%▼1.017.23%▲0.317.4%▲0.216.56%▼0.815.96%▼0.615.9%▼0.1
DIIs4.06%5.66%▲1.66.99%▲1.37.05%▲0.19.52%▲2.510.53%▲1.011.23%▲0.711.63%▲0.4
Public25.18%25.17%▼0.024.82%▼0.424.48%▼0.324.83%▲0.324.6%▼0.224.57%▼0.024.25%▼0.3

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales186.3175.2205.853.261.456.160.759.566.467.3
Expenses185.5175.9193.643.451.446.149.849.254.655.1
Operating Profit0.8-0.712.29.8101010.910.311.812.2
OPM %0.43%-0.4%5.93%18.42%16.29%17.83%17.96%17.31%17.77%18.13%
Net Profit-0.4-2.432.5-10.210.55.313.65.8-6.46.6
EPS ₹-0.03-0.152.04-0.640.660.330.850.36-0.40.41

AI Insights

Revenue Trend

TTM revenue at ₹254Cr, down 66% YoY. OPM at 18%.

Debt Position

Borrowings at ₹53Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Capex Cycle

CWIP at ₹4Cr (3% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 11.63% (+10.00pp change). FIIs: 15.9% (-7.30pp change). Promoters hold 47.67%.

Margin & Efficiency

ROCE declining from 9% (Mar 2014) to 3% (Mar 2025). Working capital days: 79.

Recent Announcements